Cell-based assays for Parkinson's disease using differentiated human LUHMES cells

Acta Pharmacologica Sinica

Volumn 35, Issue 7, 2014, Pages 945-956

  Zhang, Xiao Min ^a,b   Yin, Ming ^a   Zhang, Min Hua ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b GLAXOSMITHKLINE   (China)

Author keywords

Cell based assay; Cytotoxicity; Dopaminergic neuron; GW8510; LUHMES cell; Parkinson's diseas; SB216763; synuclein

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ADENOSINE TRIPHOSPHATE; BACULOVIRUS VECTOR; CASPASE 3; CASPASE 7; CYCLIC AMP; CYCLIN DEPENDENT KINASE INHIBITOR; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GW 8510; MESSENGER RNA; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROPROTECTIVE AGENT; NEUROTOXIN; NUCLEAR RECEPTOR RELATED FACTOR 1; SYNUCLEIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 1 METHYL 4 PHENYLPYRIDINIUM; ALPHA SYNUCLEIN; CYCLIN DEPENDENT KINASE 2; GLYCOGEN SYNTHASE KINASE 3; GW8510; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION ASSAY; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; LUND HUMAN MESENCEPHALIC CELL; MITOSIS; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; GENETICS; MESENCEPHALON; METABOLISM; NERVE CELL; PROCEDURES;

1-METHYL-4-PHENYLPYRIDINIUM; ALPHA-SYNUCLEIN; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CYCLIN-DEPENDENT KINASE 2; DRUG EVALUATION, PRECLINICAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; MALEIMIDES; MESENCEPHALON; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 84903834290     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.36     Document Type: Article

References (32)

1. De Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Balderes¬chi M, et al. Prevalence of Parkinson's disease in Europe: A collabora¬tive study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S21-3
2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384-6
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991; 114: 2283-301
4. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-66
5. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47: S2-9
6. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000; 55: S13-20
7. Alberio T, Lopiano L, Fasano M. Cellular models to investigate bio¬chemical pathways in Parkinson's disease. FEBS J 2012; 279: 1146-55
8. Påhlman S, Mamaeva S, Meyerson G, Mattsson ME, Bjelfman C, Ortoft E, et al. Human neuroblastoma cells in culture: A model for neuronal cell differentiation and function. Acta Physiol Scand Suppl 1990; 592: 25-37
9. Grau CM, Greene LA. Use of PC12 cells and rat superior cervical gan¬glion sympathetic neurons as models for neuroprotective assays rel¬evant to Parkinson's disease. Methods Mol Biol 2012; 846: 201-11
10. Schule B, Pera RA, Langston JW. Can cellular models revolutionize drug discovery in Parkinson's disease?. Biochim Biophys Acta 2009; 1792: 1043-51
11. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW. Neuroprotection and neuronal differentiation studies using substantia nigra dopa¬minergic cells derived from transgenic mouse embryos. J Neurosci 1999; 19: 10-20
12. Schmidt F, Champy P, Seon-Meniel B, Franck X, Raisman-Vozari R, Figadere B. Chemicals possessing a neurotrophin-like activity on do¬paminergic neurons in primary culture. PLoS One 2009; 4: E6215
13. Lotharius J, Falsig J, van Beek J, Payne S, Dringen R, Brundin P, et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 2005; 25: 6329-42
14. Scholz D, Pöltl D, Genewsky A, Weng M, Waldmann T, Schildknecht S, et al. Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 2011; 119: 957-71
15. Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 1984; 100: 49-54
16. Singer TP, Ramsay RR, McKeown K, Trevor A, Castagnoli NE Jr. Mech¬anism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyr¬idine (MPTP). Toxicology 1988; 49: 17-23
17. Lotharius J, O'Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 2000; 275: 38581-8
18. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7
19. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggrega¬tion of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998; 152: 879-84
20. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lin¬coln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167-9
21. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, et al. Double-knockout mice for alpha-And beta-synucleins: Effect on syn¬aptic functions. Proc Natl Acad Sci U S A 2004; 101: 14966-71
22. Studer L. Culture of substantia nigra neurons. Curr Protoc Neurosci 2001; Chapter 3: Unit
23. Hongo H, Kihara T, Kume T, Izumi Y, Niidome T, Sugimoto H, et al. Gly¬cogen synthase kinase-3beta activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization. Bio¬chem Biophys Res Commun 2012; 426: 94-9
24. Diaz-Corrales FJ, Asanuma M, Miyazaki I, Miyoshi K, Hattori N, Ogawa N. Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells. Neurotox Res 2008; 14: 295-305
25. Smith PD, O'Hare MJ, Park DS. CDKs: Taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol Med 2004; 10: 445-51
26. Alvira D, Tajes M, Verdaguer E, de Arriba SG, Allgaier C, Matute C, et al. Inhibition of cyclin-dependent kinases is neuroprotective in 1-methyl-4-phenylpyridinium-induced apoptosis in neurons. Neurosci¬ence 2007; 146: 350-65
27. Petit-Paitel A, Brau F, Cazareth J, Chabry J. Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neu¬ronal cell death of MPTP/MPP-Treated neurons. PLoS One 2009; 4: E5491
28. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40
29. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34
30. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57-71
31. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009; 106: 20051-6
32. Schildknecht S, Karreman C, Pöltl D, Efrémova L, Kullmann C, Gutbier S, et al. Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. ALTEX 2013; 30: 427-444.